Jacobio Pharmaceuticals Group Co., Ltd. (Jacobio Pharma) disclosed a further on-market share buyback on 24 June 2026, repurchasing 108,600 ordinary shares at prices between HK$4.29 and HK$4.33, for a volume-weighted average cost of HK$4.31 per share. The aggregate consideration amounted to HK$0.47 million.

Following the transaction, Jacobio’s issued share capital excluding treasury shares declined marginally by 0.0139% to 783.09 million shares, while treasury stock rose to 8.67 million shares. Total issued shares remained unchanged at 791.76 million.

The purchases form part of the repurchase mandate approved on 5 June 2026, which authorises the company to buy back up to 78.37 million shares. Cumulative repurchases under this mandate now stand at 639,300 shares, equivalent to 0.0816% of the issued share base on the mandate date.

In accordance with Hong Kong listing requirements, Jacobio is subject to a moratorium on issuing new shares or disposing of treasury shares until 24 July 2026.